Patents Examined by Danah Al-Awadi
  • Patent number: 11642292
    Abstract: An aqueous cosmetic includes water, a polyhydric alcohol and carminic acid. A content of the carminic acid is greater than or equal to 0.2 mass % and less than 2 mass % based on a total amount of the aqueous cosmetic.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: May 9, 2023
    Inventor: Shunpei Takezawa
  • Patent number: 11638757
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: May 2, 2023
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
  • Patent number: 11633356
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 25, 2023
    Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
    Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
  • Patent number: 11623019
    Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: April 11, 2023
    Assignee: Sofregen Medical, Inc.
    Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
  • Patent number: 11617815
    Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 4, 2023
    Assignee: Sofregen Medical, Inc.
    Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
  • Patent number: 11576856
    Abstract: The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: February 14, 2023
    Assignee: AMGEN INC.
    Inventors: Andrew Phillip Spasoff, Susanne Therese Atkinson, Adrian Bennis, Erwin Freund
  • Patent number: 11554088
    Abstract: An oily stick-shaped cosmetic containing (A) a partially hydrogenated jojoba ester, (B) Japan wax, (C) a higher fatty acid, and (D) a dimer acid ester.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: January 17, 2023
    Inventor: Hidekazu Yano
  • Patent number: 11540990
    Abstract: Oil compositions containing two or more mixtures selected from the group consisting of a lauroyl glutamic acid diester mixture having a melting point higher than 33° C., a lauroyl glutamic acid diester mixture having a melting point of 20 to 32° C., and a lauroyl glutamic acid diester mixture having a melting point of ?20° C. or lower can simultaneously achieve the texture properties (melting smooth feel, uniform spread over the lip surface, and transparent gloss), stability (such as improvement in breaking strength and improvement in temporal stability of the breaking strength), and the elasticity necessary for improving makeup duration of a lipstick.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 3, 2023
    Assignee: AJINOMOTO CO., INC.
    Inventors: Shuvendu Biswas, Shiori Oono
  • Patent number: 11534406
    Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 27, 2022
    Assignee: Tillotts Pharma AG
    Inventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
  • Patent number: 11529419
    Abstract: There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: December 20, 2022
    Assignee: ALTUS FORMULATION INC.
    Inventors: Marc Lemieux, Bradut Mitrasca, Sonia Gervais, Damon Smith
  • Patent number: 11529296
    Abstract: The present invention relates to a water-releasing stick-type cosmetic and, specifically, to a water-releasing stick-type cosmetic containing: an oily portion; and a water-releasing ingredient that is spread out in the oily portion, wherein the water-releasing ingredient has water particles encompassed by a plurality of plate-shaped materials to which emulsifiers are bound. According to the present invention, provided is a water-releasing stick-type cosmetic, which can provide a moist and cool feeling by directly supplying a large quantity of water, has excellent dosage form stability by having a hardness suitable for stick cosmetics, and simultaneously has excellent application texture, excellent storage stability and excellent color tone.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 20, 2022
    Assignee: Sunjin Beauty Science Co., Ltd.
    Inventor: Sung Ho Lee
  • Patent number: 11517534
    Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: December 6, 2022
    Assignee: Tillotts Pharma AG
    Inventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
  • Patent number: 11517538
    Abstract: Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: December 6, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Eric A. Appel, Mark W. Tibbitt, Robert S. Langer
  • Patent number: 11491087
    Abstract: The present invention relates to a method of capturing and stabilising volatile thiol malodour generated on the human skin, comprising steps of: i) contacting the human skin with a substrate, ii) absorbing said thiol into the substrate, and iii) reacting said thiol with a thiol-capture agent. The invention also relates to a method of quantifying said thiol, a method of assessing the deodorizing performance of a cosmetic composition on the human skin.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 8, 2022
    Assignee: CONOPCO, INC.
    Inventors: Susan Bates, David Mark Haddleton, Rachel Alice Hand, Gavin William Kirby, Ezat Khoshdel
  • Patent number: 11484579
    Abstract: A multicomponent treatment program for kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 1, 2022
    Inventor: Edgar L. Hull, Jr.
  • Patent number: 11478416
    Abstract: A dialkyl amidoamine which is the reaction product of a polyamine, a monocarboxylic acid, or a triglyceride or derivative thereof, and optionally an epoxide-containing compound is described. The dialkyl amidoamine may be used as a conditioning agent or anti-frizz agent useful in personal care applications, particularly in the conditioning of hair. The preparation and use of a conditioning agent and an anti-frizz agent comprising the dialkyl amidoamine are also described.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 25, 2022
    Assignee: Croda Inc.
    Inventors: Abel Pereira, Christina Bishop, Steven Jez Uzupis, Farahdia Edouard, Marni Dexter, Erik Gunderman
  • Patent number: 11458098
    Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: October 4, 2022
    Assignee: Insmed Incorporated
    Inventors: Ju Du, Adam Plaunt, Vladimir Malinin
  • Patent number: 11413374
    Abstract: There is described a multiphasic osteochondral scaffold for osteochondral defect repair, the scaffold comprising a bone phase and a cartilage phase, wherein the bone phase comprises a support matrix and the cartilage phase comprises a polymeric matrix, and the scaffold comprises a non-porous layer between the bone phase and the cartilage phase. Also described is a multiphasic osteochondral scaffold for osteochondral defect repair, the scaffold comprising a bone phase and a cartilage phase, wherein the bone phase comprises a support matrix and the cartilage phase comprises a polymeric matrix, and wherein the support matrix is tapered so that the dimensions of the support matrix are less at the lower end of the support matrix than at the upper end of the support matrix.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 16, 2022
    Assignee: UCL BUSINESS LTD
    Inventors: Chaozong Liu, Gordon Blunn
  • Patent number: 11389470
    Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: July 19, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Olivier Clement, Christophe Cellier, Claire Wilhelm, Florence Gazeau, Amanda Brun, Gabriel Rahmi
  • Patent number: 11351120
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 7, 2022
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Stephen D. Collins, Peter J. Goldstein, Joshua T. Johnstone